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a b s t r a c t
Background: Abnormal thyroid hormonemetabolism inﬂuences the occurrence and progress of coronary
heart disease (CHD). The aim of the present study was to analyze the severity of coronary artery lesions
and the prognosis of thyroid dysfunction patients admitted for coronary angiography (CAG).
Methods: From July 2011 to July 2012, 605 consecutive patients with suspected coronary heart disease
admitted for CAG were selected. The patients were divided into three groups, based on their thyroid
function prior to CAG: euthyroid group (n=455 patients), low T3 syndrome group (n=96 patients), and
hypothyroidism group (n=54 patients). All patients underwent CAG. Then the severity of coronary artery
lesions was assessed by Gensini scores. All patients were followed up for major adverse cardiac events.
Results: The prevalence of CHD in low T3 syndrome group and hypothyroidism group was signiﬁcantly
higher than that in the euthyroid group (p<0.001 and p=0.004, respectively). Moreover, the severity of
coronary artery lesions in low T3 syndrome group and hypothyroidism group was signiﬁcantly greater
than that in theeuthyroidgroup (allp<0.001).Multinomial logistic regressionanalysis demonstrated that
low T3 syndrome was an independent risk factor of coronary artery moderate [odds ratio (OR) =4.268,
95% CI: 3.294–7.450, p=0.016] and severe (OR=4.294, 95% CI: 2.259–9.703, p<0.001) lesions. The mean
duration of follow-upwas 15.3±3.8months; patientswith thyroid dysfunction had a signiﬁcantlyworse
prognosis as compared to those in the euthyroid group for the composite end-point (p<0.01). Moreover,
the incidence of the composite end-point (all-cause death, non-fatal myocardial infarction, and coro-
nary revascularization) was signiﬁcantly higher in low T3 syndrome group and hypothyroidism group
compared with that of in the euthyroid group (all p<0.001).
Conclusions: The patients with hypothyroidism and low T3 syndrome had a high prevalence of CHD,
increased severity of coronary artery lesions and poor prognosis.
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The cardiovascular system is one of the main target organ sys-
ems onwhich the thyroid hormones act [1,2]. The active hormone
riiodothyronine (T3) 80% of which is derived from peripheral con-
ersion of prohormone thyroxine (T4) exerts its biological effect
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[3]. The study has shown that T3 plays an important role in regulat-
ing the heart rate and cardiac contractility and arterial peripheral
resistance [1,2]. Abnormal thyroid hormone metabolism leads to
different forms of heart disease: T3 level is negatively corre-
lated with the prevalence of coronary heart disease (CHD) [4];
hypothyroidism could accelerate the process of atherosclerosis and
increase the risk of cardiovascular events [5]; low T3 syndrome
increases the mortality of acute myocardial infarction patients and
is a strong predictor of cardiac death [6]. However, do thyroid
dysfunction patients have increased severity of coronary artery
lesions and prognosis? Few studies in this aspect were seen in
China. The aim of the present study was to assess the severity of
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tudy population
The study enrolled 605 consecutive patients with suspected
HD who were admitted to the Department of Cardiology in
hengzhou University People’s Hospital for coronary angiogra-
hy (CAG) from July 2011 to July 2012. The exclusion criteria
ere as follows: (1) previous CAG; (2) therapy with amiodarone;
3) subclinical hypothyroidism, clinical hyperthyroid, subclinical
yperthyroidism; (4) chronic renal insufﬁciency; (5) clinical signs
f sepsis or cachexia or any other severe systemic disease.
The present study was designed as a prospective observational
tudy. All participants signed consent forms, and the approval of
he institutional review board was obtained prior to the initiation
f the study.
hyroid hormone determination
Venous blood samples on empty stomach were performed
efore the CAG in order to measure the levels of triglycerides (TG),
otal cholesterol (TC), low-density lipoprotein cholesterol (LDL-C),
igh-density lipoprotein cholesterol (HDL-C), apolipoprotein A1
Apo-A1), and apolipoprotein B100 (Apo-B100) assayed using the
outine laboratory techniques. In addition, 3mL of venous blood
amplesonempty stomachwere rapidly centrifuged, andplasmatic
oncentration of free T3 (fT3), free T4 (fT4), and hypersensitive thy-
oid stimulating hormone (hTSH) was measured by a completely
utomated ADVIA Centaur XP system (Siemens Medical Solutions
iagnostics, Tarrytown, NY, USA). The reference intervals for our
aboratory are as follows: fT3 3.5–6.5pmol/L, fT4 11.5–22.7pmol/L,
nd hTSH 0.55–4.78uIU/mL. We divided the patients into three
roups on the basis of thyroid hormone proﬁle [7]: euthyroid group
patients with normal values of hTSH, fT3 and fT4), low T3 syn-
romegroup (patientswith fT3<3.5pmol/L, normal values of hTSH
nd fT4), hypothyroid group (patients with hTSH>4.78uIU/mL,
T3<3.5pmol/L or/and fT4<11.5pmol/L).
AG and the severity of coronary artery lesions
CAG was done by the Judkins technique via radial or femoral
rtery. Each examination was reviewed by two interventional car-
iologists who were blinded to the study plan and to each other.
HD was deﬁned as a greater than 50% stenosis by visual assess-
ent in at least one major vessel or principal side branch. The
ensini score was used to evaluate the severity of coronary artery
esions. The coronary artery lesions were divided into three cate-
ories according to Gensini scores [8]: coronary arterymild lesions
Gensini score 0–20), coronary artery moderate lesions (Gensini
core 21–33), and coronary artery severe lesions (Gensini score
33). Contrast media (CM) used for CAG were ultravist solution or
istodenz solution.
linical follow-up
We obtained follow-up information from a survey of the
atients’ records, telephone interviews, or medical visits at the
utpatient clinic. The end time of follow-up was May 2013.
ajor adverse cardiac events were carefully recorded, including
ll-cause death, non-fatal myocardial infarction (MI), and coronary
evascularization. All-cause death was deﬁned as a composite of
eath from any cause. Non-fatal MI was deﬁned as the presence
f typical chest pain, electrocardiographic ST-segment elevation
ith or without Q waves, as well as serum cardiac enzyme eleva-
ions at least twofold upper limit of the normal range. Coronarylogy 64 (2014) 496–500 497
revascularization was deﬁned as a repeat percutaneous coronary
intervention during follow-up.
Statistical analysis
Continuous data were expressed as means± SD, and the differ-
ences were analyzed with one-way analysis of variance (ANOVA,
normal distribution) or Mann–Whitney U test (abnormal distribu-
tion or unequal variances). Categorical variables were presented
by frequency counts, and the differences were tested using the chi-
square test or Fisher exact test. The Kruskal–Wallis test was used
for ordered categorical data with the severity of coronary artery
lesions, and the risk factors of the severity of coronary artery lesions
were estimated bymultinomial logistic regression analysis. Cumu-
lative event rates were evaluated using Kaplan–Meier estimates
and compared using a log-rank test. A multivariable Cox propor-
tional hazardsmodelwas used to evaluate the association between
thyroid function and adverse events after adjustment for baseline
that differed signiﬁcantly among the thyroid function groups. Uni-
variable predictors of adverse events with less than 0.05 of p value
were allowed to enter the model. We presented the results as haz-
ard ratio (HR) and 95% conﬁdence intervals (CI) and p values. A
proportional-hazards model was developed by using enter selec-
tion. Statistical signiﬁcance was considered to be p<0.05 among
the three groups and p<0.0167 between two groups. All statis-
tical analyses were performed with SPSS17.0 software (SPSS Inc,
Chicago, IL, USA).
Results
We divided the 605 patients into three groups on the basis of
thyroid hormone proﬁle: euthyroid group (n=455, 75.2%); low T3
syndrome group (n=96, 15.7%); and hypothyroid group (n=54,
8.9%). Table 1 reports the clinical characteristics of the study pop-
ulation. As compared to euthyroid patients, low T3 syndrome
patients and hypothyroid patients had signiﬁcantly higher preva-
lence of acute coronary syndrome (ACS), TC, and LDL-C levels (all
p<0.01). There were no signiﬁcant differences in other cardiovas-
cular risk factors.
CAG showed that there were 280 (61.5%) patients with CHD
in the euthyroid group, 80 (83.3%) patients with CHD in the low
T3 syndrome group, and 44 (81.5%) patients with CHD in the
hypothyroid group, respectively. Statistical analysis showed that
the prevalence of CHD in three groups had a signiﬁcant difference
(p<0.01). The prevalence of CHD in the low T3 syndrome group
and hypothyroidism group was signiﬁcantly higher than that in
the euthyroid group (p<0.001 and p=0.004, respectively); the total
amount of CM administered with CAG in the three groups was
31.9±12.3 g, 30.6±11.1 g, and 30.0±9.7 g, in groups 1, 2, and 3,
respectively, and no signiﬁcant difference was found among the
three groups (p>0.05). All patients had no thyroid crisis during
their hospitalization.
Table 2 shows the severity of coronary artery lesions according
to the Gensini score in the three groups, the severity of coro-
nary artery lesions in the three groups had a signiﬁcant difference
(p<0.05), the severity of coronary artery lesions in the low T3
syndrome group and the hypothyroidism group were signiﬁcantly
greater than that in the euthyroid group (all p<0.001). Table 3
shows the signiﬁcant results of multinomial logistic regression
analysis about the severity of coronary artery lesions. In themodel,
we have included clinical variables in Table 1; coronary artery
mild lesion was regarded as a reference category. Results showed
that low T3 syndrome was an independent risk factor of moderate
(OR=4.268, 95% CI: 3.294–7.450, p=0.016) and severe (OR=4.294,
95% CI: 2.259–9.703, p<0.001) coronary artery lesions.
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Table 1








Age, years, mean± SD 64.5±11.3 67.2±9.2 64.4±17.1 0.14
Sex, female, n (%) 139 (30.5%) 35 (36.5%) 22 (40.7%) 0.21
Smoker, n (%) 141 (30.9%) 27 (28.1%) 11 (20.4%) 0.26
Hypertension, n (%) 198 (43.5%) 46 (47.9%) 28 (51.9%) 0.42
Diabetes, n (%) 76 (16.7%) 19 (19.8%) 10 (18.5%) 0.75
Arrhythmias, n (%) 68 (14.9%) 10 (10.4%) 8 (14.8%) 0.51
ACS, n (%) 143 (31.4%) 44 (45.8%)* 26 (48.1%)* <0.01
TC, mmol/L, mean± SD 4.21±1.05 4.42±1.05* 4.38±0.96* <0.01
TG, mmol/L, mean± SD 2.01±1.62 2.24±1.66 2.47±1.94 0.26
HDL-C, mmol/L, mean± SD 1.05±0.27 0.96±0.21 1.12±0.28 0.09
LDL-C, mmol/L, mean± SD 2.29±0.51 2.69±0.67* 2.42±0.81* <0.01
Apo-A1, g/L, mean± SD 1.22±0.12 1.26±0.16 1.38±0.23 0.16
Apo-B100, g/L, mean± SD 0.78±0.02 0.98±0.21 0.84±0.11 0.34
ACS, acute coronary syndrome; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo-A1,
apolipoprotein A1; Apo-B100, apolipoprotein B100.
* p<0.001 for comparison with euthyroid group.
Table 2
The analysis of the severity of coronary artery lesions.
Euthyroid Low T3 syndrome* Hypothyroidism*
Mild, n (%) 157 (34.5) 16 (16.7) 11 (20.4)
Moderate, n (%) 208 (45.7) 38 (39.6) 23 (42.6)
Severe, n (%) 90 (19.8) 42 (43.8) 20 (37.0)
* p<0.001 for comparison with euthyroid group.
Table 3
The analysis of multinomial logistic regression about the severity of coronary artery
lesions.
b p value OR 95% CI for OR
Moderate
Low T3 syndrome 1.362 0.016 4.268 3.294–7.450
ACS 1.263 0.003 3.466 1.347–6.912
LDL-C 1.437 <0.001 3.540 1.641–5.643
Severe
Low T3 syndrome 1.472 <0.001 4.294 2.259–9.703
ACS 1.768 <0.001 5.967 2.436–10.902

















Moronary artery mild lesion was regarded as reference category.
, regression coefﬁcient; OR, odds ratio; ACS, acute coronary syndrome; LDL-C, low-
ensity lipoprotein cholesterol.
The follow-up included 580 (92.8%) out of the overall 625
atients. The mean duration of follow-up was 15.3±3.8 months.
able 4 shows the major events of the three groups in this study.
ig. 1 shows the Kaplan–Meier survival curves for the composite
nd-point (all-cause death, non-fatal MI, and coronary revascu-
arization). Patients with thyroid dysfunction had a signiﬁcantly
oorer prognosis as compared to the euthyroid group (p<0.01).
he group analysis showed that the low T3 syndrome group and
ypothyroidism group had a signiﬁcant difference in survival as
egards composite end-point compared to the euthyroid group (all
< 0.001).
able 4





All-cause death, n (%) 5 (1.2)
Non-fatal MI, n (%) 14 (3.3)
Revascularization n (%) 8 (1.9)
The composite end-point, n (%) 27 (6.3) 1
he composite end-point includes all-cause death, non-fatal MI, and coronary revascular
I, myocardial infarction.
* p<0.001 for comparison with euthyroid group.Fig. 1. Survival curves related to composite event (all-cause death, non-fatal
myocardial infarction, and coronary revascularization) in three groups.
Table 5 shows the results of the analysis of COX for com-
posite end-point. In the model, we included clinical variables in
Table 1 that resulted in signiﬁcant correlationwith the events in the
univariate analysis. The presence of the lowT3 syndrome, hypothy-
roidism group, ACS, and LDL were independent prognostic factors






2 (2.3) 1 (2.0) 0.716
6 (6.8) 4 (8.3) 0.071
4 (4.5) 3 (6.3) 0.116
2 (13.6)* 8 (16.7)* 0.014
ization.
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Table 5
Multivariate survival COX proportional hazards analysis.
b SE(b) Wald p value Exp(b) 95% CI for Exp(b)
Low T3 syndrome vs. euthyroid 0.683 0.159 4.126 0.022 1.892 1.381–2.558
Hypothyroid vs. euthyroid 0.932 0.406 5.927 0.004 1.334 1.073–1.806
ACS 1.066 0.306 12.160 <0.001 2.904 1.595–5.287
TC −0.112 0.160 0.491 0.483 0.894 0.653–1.224
HDL-C 0.136 0.117 1.145 0.084 1.145 0.818–1.602


















































l, regression coefﬁcient; CI, conﬁdence interval; Exp(b), risk according to progno
oronary syndrome; TC, total cholesterol; HDL-C, high-density lipoprotein choleste
iscussion
The present study demonstrated that low T3 syndrome and
ypothyroidism were associated with a higher prevalence of CHD,
ore serious coronary artery lesions, and poorer prognosis com-
ared to euthyroidism. The reason could be dyslipidemia and
ndothelial dysfunction affected by thyroid hormone.
Thyroid hormones could regulate blood lipid levels, and then
nﬂuence the occurrence and progress of CHD. The promoter of the
DL receptor gene contains a thyroid hormone responsive element
hich can promote fT3 to increase the expression of LDL recep-
ors, therefore increasing the clearance of LDL [9]. Several studies
ound that hypothyroidism could increase the levels of TC and LDL-
[10], and accelerate the development of atherosclerosis and the
rogress of CHD [2,11]. Several studies also have pointed out a
elationship between the serum thyroid hormone levels and the
evelopment of atherosclerosis. Tatar et al. [12] conﬁrmed that
erum fT3 levels were inversely correlatedwith carotid atheroscle-
osis and low serum fT3 level was an important determinant of
arotid atherosclerosis. Coceani et al. [4] reported that serum fT3
evels were inversely correlated with the presence of CHD and the
ow T3 syndrome indicated an adverse prognosis, even after adjus-
ing for the traditional coronary risk factors.
In addition to dyslipidemia, hypothyroidism may also lead to
ndothelial dysfunction, hypercoagulability, impaired ﬁbrinoly-
is, hyperhomocysteinemia, systemic inﬂammation, and platelet
bnormalities [5]. Low thyroid hormones altered the arterial mus-
le structure, and then caused thickening of the vessel wall. Several
eports indicated thathypothyroidismwasan independent risk fac-
or for atherosclerosis andMI [13], evenwhen hypothyroidismwas
reated, a residual increased risk of cardiovascular diseases may
ersist [14]. These changes in arterial muscle structure and ves-
el wall were independent of hypercholesterolemia and emerged
apidly after hypothyroidism took shape [15].
Ertas et al. [16] found that T3 levels within the physiological
ange were inversely correlated with the presence and severity of
HD. And free T3was signiﬁcantly lower in subjectswith CHDcom-
ared to those without CAD (4.0±0.7pmol/L vs. 4.6±0.6pmol/L,
< 0.001). Moreover, fT3 was lower in patients with severe com-
ared to mild CAD (3.9±0.7pmol/L vs.4.5±0.6pmol/L, p<0.001).
ogistic regression analysis demonstrated that the lower FT3 levels
ereassociatedwith thepresence (OR=0.266, 95%CI: 0.097–0.731,
= 0.01) and severity (OR=0.238, 95% CI: 0.083–0.685, p=0.008)
f CHD. Low T3 syndrome may produce a hypothyroid-like syn-
rome that contributes to the worsening or exacerbation of the
ntrinsic cardiac diseases [1,17]. In our study, hypothyroidism and
ow T3 syndrome, whose T3 levels were below the physiolog-
cal range, increased the incidence of CHD and the severity of
oronary artery lesions. Moreover, multinomial logistic regression
nalysis demonstrated low T3 syndrome was an independent risk
actor of moderate (OR=4.268, 95% CI: 3.294–7.450, p=0.016) and
evere (OR=4.294, 95% CI: 2.259–9.703, p<0.001) coronary artery
esions.riables; SE(b), standard error of b; Wald, coefﬁcient of the Wald test; ACS, acute
L-C, low-density lipoprotein cholesterol.
Some studies [18–20] have observed a relationship between the
fT4 andTSH levels and thepresence or severity of theCHD, but Ertas
et al. [16] took the opposite view. In the present study, T4 and TSH
were not found to be related to the presence and severity of CHD.
Some possible reasons may be those of differences in sample sizes,
study populations, various ethnic groups, and laboratory methods.
Many studies [6,21–23] concluded that hypothyroidismand low
T3 syndrome were associated with the increased risk in deaths
and the composite end-point (cardiac death and non-fatal MI).
Marraccini et al. [23] indicated that hypothyroidism and low T3
syndrome had a signiﬁcantly worse prognosis both for the over-
all and cardiac death as compared to euthyroidism, and also the
incidence of the composite end-point (cardiac death and nonfa-
tal MI). In addition, low T3 had an independent prognostic value
both for the total mortality and for the composite end-point (non-
fatal MI and cardiac death). In the present study, hypothyroidism
and low T3 syndrome had a signiﬁcantly worse prognosis only for
the composite end-point (all-cause death, non-fatal MI, and coro-
nary revascularization) as compared to euthyroidism. Moreover,
hypothyroidism and low T3 syndrome were independent risk fac-
tors for the composite end-point.
In non-pathological conditions, there is a Wolff–Chaikoff effect
[24] that the thyroid gland has the ability to handle an acute iodide
overload by inhibition of iodide organiﬁcation, which leads to a
transient reduction in hormone synthesis. In pathological condi-
tions, theWolff–Chaikoff effect is insufﬁcient to protect the thyroid
gland and thyreotoxicosis may ensue [25]. In our study, all patients
with thyroid dysfunction did not appear to have thyreotoxicosis.
This was possibly because the symptomatic patients of thyroid
dysfunction were treated with medicines before CAG.
Study limitations
Themain limitation of this study is being a single center of clin-
ical research which has a limited number of study subjects. These
subjectswerenot selected fromthegeneral population. It is alsonot
an ideal method to identify the severity of coronary artery lesions
by Gensini scores. In addition, the follow-up time is not as long as
in previous studies.
Conclusion
In the present study, we demonstrated that low T3 syndrome
andhypothyroidismhadahighprevalenceof CHD, increased sever-
ity of coronary artery lesions, and poor prognosis.
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